Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
about
Antibiotic treatment for Helicobacter pylori: Is the end coming?Efficacy of Magnetic Sphincter Augmentation versus Nissen Fundoplication for Gastroesophageal Reflux Disease in Short Term: A Meta-Analysis.Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Cytochrome P450 in living donor liver transplantation.Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication.Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium).Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.Role of bismuth in improving Helicobacter pylori eradication with triple therapy.Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study.Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype.Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial.Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors.Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.
P2860
Q26777623-FB30A22D-BA0E-43F5-901A-C0B7C0B0267BQ33561533-63BF0F85-DA06-4771-9EFC-5023006330B9Q33639114-31801C1B-6098-40AC-AE38-9F8E14C7DF6CQ35632041-D612575B-A0DC-4846-A20B-57D0C4AFC137Q35884102-FA232BB3-0474-4890-A36D-5B47FFE65132Q38205882-3DDA6CDD-DC1F-484A-8974-39A3F8E9D599Q38219028-63F14742-3634-498C-A3D6-6C0D81DB2D8BQ38599606-5FB312D7-B353-47B2-AA98-1743D943C1FEQ38723877-074F0D75-4C13-4D88-8B8C-C1533FE3B5A1Q39115196-846E27F1-6124-41E9-83B8-5141C8A36D0AQ39196966-94F961DD-20D0-4AA4-840E-AB45088AD215Q39496571-2BD0408B-7B95-45FF-8603-D1DBF61C17C6Q39496607-A5B8FAA5-6172-4BFF-9A2F-2744D78A9F54Q40268942-E6AE648C-F641-418B-8A6D-B9F1152A9781Q40316973-C26320AD-0345-4F33-99B0-1B9142B8852BQ40702356-4197CA03-77CA-4199-83EF-CA49C487F03BQ41706384-42589D8D-C272-4C68-8C57-C418FF3E22D0Q41867496-B40494D1-1B2D-457D-BCE8-D13F2DB6A7D7Q47197069-F218EEBF-CDE3-461A-91A2-CA0397BD00F7Q55280841-45C49136-AE1F-4F77-BAC4-2B6F5158AFB1
P2860
Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Twice-daily dosing of esomepra ...... , rabeprazole or lansoprazole.
@en
Twice-daily dosing of esomepra ...... , rabeprazole or lansoprazole.
@nl
type
label
Twice-daily dosing of esomepra ...... , rabeprazole or lansoprazole.
@en
Twice-daily dosing of esomepra ...... , rabeprazole or lansoprazole.
@nl
prefLabel
Twice-daily dosing of esomepra ...... , rabeprazole or lansoprazole.
@en
Twice-daily dosing of esomepra ...... , rabeprazole or lansoprazole.
@nl
P2093
P2860
P356
P1476
Twice-daily dosing of esomepra ...... , rabeprazole or lansoprazole.
@en
P2093
H Ichikawa
H Miyajima
K Sugimoto
M Iwaizumi
M Sugimoto
P2860
P304
P356
10.1111/APT.12492
P407
P577
2013-09-16T00:00:00Z